From left to right: Adam Koppel (Bain Capital Life Sciences), Mike Bozik (Knopp Biosciences CEO) and Clive Meanwell (Population Health)
July 12, 2022 07:01 AM EDT
Deals
Bioregnum

No sur­ren­der: A group of mar­quee biotech play­ers bets on the $350M PhI­II res­ur­rec­tion sto­ry of a heavy­weight con­tender

Any­one read­ing Bio­gen’s press re­lease on the flat fail­ure of dex­pramipex­ole in treat­ing ALS couldn’t over­look the note of fi­nal­i­ty then R&D chief Doug Williams …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Judge halts some NIH cuts af­ter 22 states sue

Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works

Decade af­ter $8B deal, Roche of­floads In­ter­Mune to mys­te­ri­ous spe­cial­ty phar­ma

Eli Lil­ly inks $630M deal for Phase 1 MASH can­di­date

Boehringer In­gel­heim touts suc­cess in sec­ond Phase 3 lung fi­bro­sis tri­al

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times